An observational study in Early Diagnosis of Colorectal Cancer and Adenoma, sponsored by Xijing Hospital of Digestive Diseases. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-24.
Sponsored by Xijing Hospital of Digestive Diseases · Observational
In summary, our study demonstrated the methylation sites of SFRP1 gene promoter in patients with colorectal cancer and adenoma and found SFRP1_16_17_18 CpG site was good performance as a diagnostic marker of colorectal cancer.
661 studies on the registry are indexed under Adenoma; 101 are open to participants now.
This study's planned enrollment of 220 is below the median of 300 across 230 observational studies indexed under Adenoma.
Browse Adenoma studies →Xijing Hospital of Digestive Diseases is the lead sponsor of 81 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
consecutive adult patients undergoing an outpatient endoscopy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
healthy volunteers
Other: no intervention
pathologically reported colorectal adenoma
Other: no intervention
pathologically reported colon cancers
Other: no intervention
pathologically reported inflammatory bowel diseases
no intervention
effectiveness of methylation markers from stool samples
assess the effectiveness of methylation markers from stool samples in colon cancer patients, colorectal adenoma patients, compared with normal volunteers
Time frame: 3 years
assess the capacities of RF model in screening potential clinical biomarkers.
Time frame: 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital of Digestive Diseases